Skip to main content

Launch of the ABCD nationwide oral semaglutide audit at ADA 2021

Today at ADA 2021, ABCD is pleased to announce the launch of the ABCD nationwide oral semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it may be more effective than the other GLP-1 receptor agonists.  Results from the ABCD semaglutide audit, presented this weekend at ADA 2021, have demonstrated significant reductions in HbA1c and weight following commencement of semaglutide in a real-world cohort that was heavier with higher baseline HbA1c levels than those in clinical trials.

Empagliflozin use is associated with reduction in alanine aminotransferase: insights from ABCD audit data practice

The ABCD Empagliflozin audit has provided valuable insights into empagliflozin use in UK based real-world practice. Additionally, data from the other SGLT2 audit programmes has demonstrated reductions in ALT as a marker of liver inflammation following commencement, with reductions much greater in those with elevated levels at baseline.

RCP Webinar: Building your career as an SAS doctor

SAS doctors play a vital role in the delivery of NHS services but can sometimes be overlooked when it comes to career development and recognition.
 
Join this webinar to hear from the chair of the RCP SAS doctor network and senior RCP officers on the latest national changes for SAS doctors, the work of the RCP SAS doctor network and how the College can support you now and in the future to build a successful and enjoyable career.

About the event

The event will focus on how SAS doctors can: